CytomX Therapeutics Inc Praluzatamab Ravtansine Phase 2 Study Results Call Transcript
Good afternoon, everyone. Thank you for standing by, and welcome to the CytomX Therapeutics Conference Call. Please be advised that today's call is being recorded. (Operator Instructions) I would now like to hand the call over to your host for today's program, Chau Cheng, CytomX's Vice President, Investor Relations and Corporate Communications. Please go ahead.
Thank you, Jonathan. Good afternoon, and thank you for joining us. Before we begin, I'd like to remind everyone that during this call, we will be making forward-looking statements. Because forward-looking statements relate to the future, they are subject to inherent uncertainties and risks, including the uncertainty surrounding the COVID-19 pandemic that are difficult to predict and many of which are outside of our control.
Important risks and uncertainties are set forth in our most recent public filings with the sec.gov. We undertake no obligation to update any forward-looking statements, whether as a result of new
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
